Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
OSR Health, Inc. reported a net loss of $6.38 million for the nine months ended September 30, 2026, an improvement from the $19.81 million loss in the prior year period. Total assets increased to $185.8 million, primarily driven by growth in intangible assets and goodwill following business combinations.
Suncrete, Inc. reported Q3 2026 financial results with revenue of $141.0 million, a 163% increase year-over-year, and a return to profitability with net income of $78 thousand. The company updated its full-year 2026 revenue guidance to a range of $408 million to $434 million, citing active Sunbelt markets tempered by project shifts and interest rate pressures.
Term
Q3 2026
“We are pleased with our performance in the third quarter, with revenue and Supplemental Adjusted EBITDA increasing 163% and 62%, respectively, compared to the second quarter which led to a 150 basis point improvement in Supplemental Adjusted EBITDA margin.”
Randall Edgar, Suncrete’s Chief Executive Officer
“Our team continues to build Suncrete’s scale”
Ned N. Fleming, III, the Company’s Executive Chairman
MetaVia Inc. reported a net loss of $13.8 million for the nine months ended September 30, 2026, compared to $11.0 million in the prior year, driven by increased research and development expenses. The company's cash position decreased to $8.8 million from $10.3 million at year-end 2025, while total stockholders' equity fell to $2.4 million.
MetaVia Inc. reported third quarter 2026 financial results and provided a corporate update on its clinical pipeline, including positive Phase 1 interim data for DA-1726 in liver-related cardiometabolic diseases. The company also announced the appointment of Dr. Sarah Browne as Chief Medical Officer and plans to initiate a Phase 2 study in MetALD and ALD in the second half of 2027.
Term
Q3 2026
“The positive interim results from our Phase 1 Part 3B study of DA-1726, a novel oxyntomodulin (OXM) analog and dual GLP-1/glucagon receptor agonist, were recently highlighted in an oral presentation at the Precision Liver Symposium. We believe these findings provide important clinical support for DA-1726's potential to treat metabolic dysfunction and alcohol-associated liver disease (MetALD), as well as alcohol-associated liver disease (ALD).”
Hyung Heon Kim, President and Chief Executive Officer
“Last month, we also expanded our clinical leadership team with the appointment of Sarah Browne, M.D., as Chief Medical Officer. Sarah brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, including leading the development of pemvidutide, a dual GLP-1/glucagon receptor agonist, through Phase 2 and establishing Phase 3 development strategies.”
Hyung Heon Kim, President and Chief Executive Officer
For the three months ended September 30, 2026, SPAR Group reported net revenue of $33.5 million and a small net income of $50,000, a significant recovery from the $8.8 million net loss in the prior year period. The company's balance sheet shows a substantial increase in accounts receivable and total liabilities, while stockholders' equity improved to $3.3 million from $0.6 million at the end of 2025.
SPAR Group reported its second consecutive quarter of profitability for the period ended September 30, 2026, despite a 19% year-over-year revenue decline to $33.5 million. The company highlighted improved gross margins of 18.9% and a significant 39% reduction in SG&A expenses following organizational streamlining. Additionally, the company announced a new three-year services agreement with a national retailer set to begin in 2027.
Term
Q3 2026
“I am pleased with our progress in returning to profitability for the second consecutive quarter. Although lower remodel activity year over year impacted revenue in the U.S., sales growth in Canada and our continued focus on higher-quality revenue drove continued profitability, resulting in positive net income, stronger gross margins year on year, and a 47% increase in Adjusted EBITDA on a year-to-date basis.”
William Linnane, President and Chief Executive Officer of SPAR Group
“Our third quarter financial performance reflects continued progress against our strategic and financial objectives. Gross margin expanded to 18.9%, notwithstanding lower U.S. revenue, while disciplined cost management drove SG&A expenses down 39% from the prior year.”
Steven Hennen, Chief Financial Officer of SPAR Group
Katapult Holdings reported a net income of $51.3 million for the nine months ended September 30, 2026, a significant improvement from the prior year, driven by a 23.8% increase in total revenues to $1.62 billion. The company's balance sheet expanded substantially following a reverse merger, with total assets growing from $1.4 billion to $3.1 billion and cash reserves increasing to $261.0 million.
Indaptus Therapeutics reported a net loss of $5.38 million for the nine months ended September 30, 2026, a significant reduction from the $12.74 million loss in the prior year period. The company's cash position strengthened to $26.60 million following significant common stock issuances and preferred stock conversions, while operating expenses decreased across both R&D and G&A categories.
BIO-key International reported Q3 2026 financial results, highlighted by a 39% increase in software license fee revenue to $1.3 million and a gross margin improvement to 90%. The company narrowed its quarterly net loss to $0.89 million and retired its remaining outstanding debt, leaving the firm effectively debt-free.
Term
Q3 2026
“Our Q3’26 results reflect the building strength of our core software business. Software license fee revenue grew 39% in Q3’26, offsetting variability in our more episodic hardware and services revenue and lifting gross margin to 90% from 77% a year ago.”
Mike DePasquale, CEO
“Year to date we have grown revenue by 14%, reduced our net loss by 42% and we retired our remaining note outstanding leaving us effectively debt free.”
Cineverse Corp. reported a significant revenue increase to $25.96 million for the quarter ended September 30, 2026, compared to $12.36 million in the prior year, driven by business growth and acquisition-related fair value adjustments. The company achieved a net income of $3.25 million for the quarter, a substantial improvement from a net loss of $5.55 million in the same period of 2025.
FRP Holdings, Inc. reported a net loss of $1.11 million for the nine months ended September 30, 2026, compared to a net income of $2.95 million in the prior year period. The decline was driven by increased general and administrative expenses and higher equity losses from joint ventures, despite a slight increase in total revenues to $32.64 million.
Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, compared to $9.0 million in the prior year period, primarily driven by a significant increase in research and development expenses for their BB-301 program. The company maintained a strong liquidity position with $176.4 million in cash and cash equivalents to fund ongoing clinical development.
Quantum Cyber reported its first revenue of approximately $1.0 million for Q3 2026 following its strategic pivot to autonomous defense. The company also announced an $8.0 million funding commitment from CEO David Lazar to support the build-out of its Bridgeport manufacturing facility and technology programs.
Counterparty
David Lazar
“The third quarter of 2026 is the quarter in which Quantum Cyber crossed from a pre-revenue strategy into an operating company. We generated our first revenue, we installed the first production equipment at our Bridgeport facility, and we resolved a legacy legal claim that had overhung our capital structure.”
David Lazar, Chief Executive Officer
“The $8.0 million funding commitment I provided to the Company on November 11, 2026 is intended to reinforce the balance sheet while we complete the build-out of the Bridgeport facility and continue to advance the Project LightShift quantum antenna program under our newly expanded field of use.”
Aardvark Therapeutics reported Q3 2026 financial results and announced that the FDA has lifted the clinical hold on its lead candidate ARD-101 for Prader-Willi Syndrome. The company ended the quarter with $60.3 million in cash, which is expected to fund operations through 2027 as it prepares for a clinical development meeting with the FDA in early 2027.
Term
Q3 2026
“The lifting of the clinical hold and the FDA’s agreement that we may conduct an open-label trial at 200 mg twice daily are important steps toward resuming clinical development of ARD-101 in PWS. We have developed a proposed clinical development plan and look forward to discussing it with the FDA. We remain committed to advancing ARD-101 for patients and families affected by PWS.”
Tien Lee, M.D., Founder and Chief Executive Officer
Fortress Biotech reported a significant net income of $129.5 million for the nine months ended September 30, 2026, primarily driven by a $158.9 million gain on the sale of a priority review voucher. This represents a substantial turnaround from the $27.5 million net loss in the prior year period, while total assets grew to $280.2 million.
Cineverse reported Q2 FY 2027 revenue of $26.0 million, a 110% year-over-year increase driven by its technology and media services segments. The company achieved net income of $3.2 million and its third consecutive quarter of positive Adjusted EBITDA, while reaffirming full-year revenue guidance of $115 million to $120 million.
Titan International provided supplemental historical financial information for the first and second quarters of 2026 and 2025, recast to reflect its ITM business as discontinued operations following a sale agreement. The filing includes formal GAAP income statements for these periods to assist investors in evaluating the company's continuing operations.
Biofrontera Inc. reported Q3 2026 net product revenue of $9.1 million, a 30% year-over-year increase driven by its photodynamic therapy products. The company achieved a significant regulatory milestone with the FDA approval of Ameluz for the treatment of superficial basal cell carcinoma. Net loss for the quarter narrowed slightly to $6.4 million compared to $6.6 million in the prior-year period.
Term
Q3 2026
“The third quarter was a pivotal one for Biofrontera. On September 9, the FDA approved Ameluz® PDT for the treatment of superficial basal cell carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that our redesigned RhodoLED® XL-C is not subject to the ITC exclusion order, which allows us to again serve the customers who rely on our large-field lamp.”
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera
DeltaSoft Corp. reported a net loss of $15,113 for the six months ended September 30, 2026, on revenues of $11,299. The company is in the development stage with an accumulated deficit of $16,022 and faces a going concern uncertainty due to limited working capital and reliance on future investment capital.
Medalist Diversified, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $20.96 million compared to a net loss of $1.59 million in the prior year, primarily driven by a $21.19 million gain on the disposal of investment properties. Total assets decreased from $77.74 million to $52.29 million as the company shifted its portfolio, including a substantial increase in marketable securities and a reduction in mortgage debt.
Owlet reported Q3 2026 revenue of $30.4 million and achieved positive net income of $1.4 million, driven by gross margin expansion and growth in its subscription service. However, the company withdrew its full-year 2026 financial outlook due to a safety update for its camera cable guard accessory, which is expected to cause retail sales interruptions and remediation expenses in Q4.
Term
Q3 2026
“We delivered a strong third quarter, driven by our focus on profitable growth. Revenue of $30.4 million was in line with our expectations, we expanded gross margin by 315 basis points, generated positive operating income and operating cash flow, and delivered $3.5 million of Adjusted EBITDA.”
Kurt Workman, Owlet’s President, Chief Executive Officer, and Co-Founder
“Today, we initiated a camera cable guard safety update for the cable guard accessory. We are providing a replacement enclosed cable guard system that we believe delivers on our commitment to elevating safety standards in the market.”
Kurt Workman, Owlet’s President, Chief Executive Officer, and Co-Founder
For the nine months ended September 30, 2026, Allarity Therapeutics reported a net loss of $12.4 million, an increase from the $7.9 million loss in the prior year period, primarily driven by higher research and development costs. The company's total stockholders' equity turned to a deficit of $2.3 million as of September 30, 2026, while cash and restricted cash increased to approximately $24.1 million.
Fortress Biotech reported Q3 2026 financial results with total net revenue increasing 9% year-over-year to $19.2 million. During the quarter, the company repaid its Oaktree credit facility in full, leaving it with no outstanding debt at the parent level, and in-licensed FB-607 for the treatment of IBS-D.
Term
Q3 2026
“The third quarter of 2026 reflected continued execution across our diversified portfolio. In September, we repaid in full our credit facility with Oaktree and we also recently announced the in-licensing of FB-607, a novel combination therapy to treat the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”).”
Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer
“With our growing royalty income from ZYCUBO® and UNLOXCYT™, and multiple potential catalysts across our partnered programs, we believe Fortress is well positioned to continue driving long-term value for our shareholders.”
Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer
PAVmed reported preliminary Q3 2026 financial results, highlighted by its subsidiary Lucid Diagnostics securing nationwide Medicare reimbursement for the EsoGuard test. The company reported $1.2 million in revenue for the quarter and noted that October saw record test volume of over 1,800 tests.
Term
Q3 2026
“We’re very encouraged by developments across the PAVmed portfolio. Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid’s largest common shareholder, PAVmed stands to benefit directly from Lucid’s substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value.”
Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer
PDS Biotechnology reported third quarter 2026 financial results, highlighting a strategic shift to PDS0301 as its lead development program. The company also noted the initial closing of a $22.3 million PIPE financing led by Nant Capital and the appointment of several new board members, including Dr. Patrick Soon-Shiong.
“During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program. We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.”
Frank Bedu-Addo, PhD, President and Chief Executive Officer
Benitec Biopharma reported financial results for its first fiscal quarter ended September 30, 2026, and announced a change in its fiscal year-end from June 30 to December 31. The company highlighted a 100% responder rate in its ongoing Phase 1b/2a study of BB-301 for OPMD and confirmed it remains on track to begin a pivotal trial in mid-2027.
Term
Q1 2027
“The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
Immunic, Inc. reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate, vidofludimus calcium. The company remains on track to report top-line data from its pivotal Phase 3 ENSURE trials in relapsing multiple sclerosis in December 2026, which could support a potential NDA submission.
Term
Q3 2026
“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history. We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS.”
Erik Lundgren, Chief Executive Officer of Immunic
“Further, our Phase 3 ENSURE trials in relapsing MS continue to be on track to report top-line data in December 2026. Our teams remain focused on this readout and readiness for a potential NDA submission should the results be positive.”
Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic
TuHURA Biosciences reported a net loss of $23.2 million for the nine months ended September 30, 2026, compared to a $23.3 million loss in the prior year. The company significantly increased its total assets to $36.2 million, primarily through the capitalization of $6.9 million in revolving credit facility debt issuance costs and $2.9 million in prepaid R&D expenses.
Verrica Pharmaceuticals reported a net loss of $35.2 million for the first nine months of 2026, driven by increased R&D and SG&A expenses. The company issued a going concern warning due to an accumulated deficit of $360.2 million and limited cash reserves of $14.4 million, though it recently secured a credit agreement for up to $27.5 million.
Yarrow Bioscience, Inc. reported a net loss of $9.7 million for the third quarter of 2026, driven by $10.7 million in operating expenses. Following a merger, the company significantly strengthened its balance sheet, ending the period with $268.9 million in cash and cash equivalents compared to $100.0 million at the end of 2025.